Completed Access to Information Requests

Follow:

  • RSS
  • Cite
About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 112 record(s)

Req # A-2022-00007

Chart showing each provision that carries a penalty, number of penalties that have been awarded for each provisions; and number of penalties that have been award at the maximum amount.

Organization: Canadian Transportation Agency

12 page(s)
September 2022

Req # A-2022-00009

Copies of any and all police reports, environment reports or studies related to the oil spill derailment in the Rural Municipality of South Qu’Appelle on Thursday, May 26, 2022, and copies of any and all information related to Pasqua First Nation reserve lands as it relates to the derailment.

Organization: Canadian Transportation Agency

0 page(s)
September 2022

Req # A-2019-001009

Adverse Drug Reactions (ADRs) for Chlorhexidine. Report numbers: 000725334, 000725411, 000725428, 000725434, 000725439, 000725442, 000725446, 000725500, 000725506, E2B_02466826, E2B_02467708, E2B_02467710, E2B_02469532, E2B_02479840, 000725624, 000725643, 000725711, 000725770, 000725821, 000725822, 000725824, E2B_02535786. ADRs for Nicotine. Report numbers: 000723298, E2B_02446830, E2B_02456263, E2B_02478261, E2B_02478354, E2B_02487552, E2B_02491357,E2B_02494777, E2B_02508747, E2B_02532088.

Organization: Health Canada

399 page(s)
September 2022

Req # A-2019-001729

Adverse Drug Reactions (ADRs) for immunoglobulin (human). Report numbers: 000729698, 000729737, 000729753, E2B_02721074, E2B_02725284, E2B_02745409, E2B_02745430, E2B_02757454, E2B_02757460, E2B_02757483, E2B_02758498, E2B_02758510, E2B_02761164, E2B_02761166, E2B_02762212, E2B_02770935, E2B_02790551, E2B_02790674, E2B_02791333, E2B_02806975.

Organization: Health Canada

584 page(s)
September 2022

Req # A-2020-000935

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-109891-294.

Organization: Health Canada

7 page(s)
September 2022

Req # A-2020-001118

Adverse Drug Reactions (ADRs). Report numbers: E2B_02194141, E2B_02194231, E2B_02196619, E2B_02196705, E2B_02196717, E2B_02199201, E2B_02199223, E2B_02199231, E2B_02199293, E2B_02199808, E2B_02200059, E2B_02201762, E2B_02202036, E2B_02202050, E2B_02202243, E2B_02202438, E2B_02202454, E2B_02202528, E2B_02203600, E2B_02204012.

Organization: Health Canada

415 page(s)
September 2022

Req # A-2020-001145

Adverse Drug Reactions (ADRs). Report numbers: E2B_02321406, E2B_02321840, E2B_02323070, E2B_02323093, E2B_02323110, E2B_02323596, E2B_02323621, E2B_02324669, E2B_02325522, E2B_02326954, E2B_02326990, E2B_02327172, E2B_02328369, E2B_02328379, E2B_02328380, E2B_02328405, E2B_02328424, E2B_02328614, E2B_02329080, E2B_02329268.

Organization: Health Canada

611 page(s)
September 2022

Req # A-2020-001184

Adverse Drug Reactions (ADRs). Report numbers: E2B_02424240, E2B_02424378, E2B_02424435, E2B_02424630, E2B_02425161, E2B_02425170, E2B_02425179, E2B_02427052, E2B_02427055, E2B_02427212, E2B_02427224, E2B_02427228, E2B_02427229, E2B_02427233, E2B_2427312, E2B_02427435, E2B_02428405, E2B_02428423, E2B_02428753, E2B_02429833.

Organization: Health Canada

289 page(s)
September 2022

Req # A-2020-001345

Adverse Drug Reactions (ADRs). Report numbers: E2B_02079242, E2B_02086576, E2B_02087040, E2B_02207354, E2B_02218589, E2B_02247236, E2B_02251088, E2B_02271649, E2B_02274332, E2B_02285866, E2B_02290975, E2B_02297390, E2B_02297391.

Organization: Health Canada

146 page(s)
September 2022

Req # A-2020-001476

Adverse Drug Reactions (ADRs) for Leflunomide. Report numbers: E2B_03053730 E2B_03053961 E2B_03054156 E2B_03054221 E2B_03054792 E2B_03056438 E2B_03057658 E2B_03070808 E2B_03070831 E2B_03071119 E2B_03073676 E2B_03068903 E2B_03075214 E2B_03075702 E2B_03075712 E2B_03076259 E2B_03081220 E2B_03081611 E2B_03081624 E2B_03081657.

Organization: Health Canada

388 page(s)
September 2022
Date modified: